Evolutionary Characteristics of HIV Type 1 Variants Resistant to Protease Inhibitors in the Absence of Drug-Selective Pressure

AIDS Research and Human Retroviruses

Volumn 19, Issue 12, 2003, Pages 1151-1153

  Boeri, Enzo ^a   Gianotti, Nicola ^b   Canducci, Filippo ^c   Hasson, Hamid ^b   Giudici, Barbara ^b   Castagna, Antonella ^b   Lazzarin, Adriano ^b,c   Clementi, Massimo ^a,c  

^a Diagnostica and Ricerca San Raffaele   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR;

ARTICLE; CASE REPORT; CODON; DRUG WITHDRAWAL; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR EVOLUTION; MOLECULAR PHYLOGENY; NEIGHBOR JOINING METHOD; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; TREATMENT FAILURE; VIRUS REPLICATION; VIRUS RESISTANCE;

DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; PHYLOGENY;

EID: 0347992799     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922203771881257     Document Type: Article

References (14)

1. Molla A, Korneyeva M, Gao Q, et al.: Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996;2:760-766.
2. Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, and Lamarre D: Impaired fitness of human immunodeficiency virus type 1 variants with high level resistance to protease inhibitors. J Virol 1997;71:1089-1096.
3. Mammano F, Petit C, and Clavel F: Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol 1998;72:7632-7637.
4. Nijhuis M, Boucher C, Schipper P, Leitner T, Schuurman R, and Albert J: Stochastic process strongly influence HIV-1 evolution during sub-optimal protease-inhibitor therapy. Proc Natl Acad Sci USA 1998;95:14441-14446.
5. Borman A, Paulous S, and Clavel F: Resistance of human immunodeficiency virus type 1 to protease inhibitors: Selection of resistance mutations in the presence and absence of the drug. J Gen Virol 1996;77:419-426.
6. Menzo S, Monachetti A, Balotta C, et al.: Biological processivity and drug-dependence of HIV-1 protease: Determinants of viral fitness in variants resistant to protease inhibitors. AIDS 2003; 17:663-671.
7. Devereux H, Youle M, Johnson M, and Loveday C: Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999;13:F123-F127.
8. Verhofstede C, Wanzeele F, Van Der Gucht B, De Cabooter N, and Plum J: Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 1999;13:2541-2546.
9. Izopet J, Souyris C, Hance A, et al.: Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype. J Infect Dis 2002;185:1506-1510.
10. Delaguerre C, Valantin M, Mouroux M, et al.: Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. AIDS 2001;15: 2189-2191.
11. Kijak G, Simon V, Balfe P, et al.: Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure. J Virol 2002;76:7000-7009.
12. Deeks S, Grant R, Wrin T, et al.: Persistence of drug resistant HIV-1 after structured treatment interruption and its impact on treatment response. AIDS 2003;17:361-370.
13. Durant J, Clevenbergh P, Halfon P, et al.: Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial. Lancet 1999;353:2195-2199.
14. Nijhuis M, Schuurman R, de Jong D, et al.: Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999;13: 2349-2359.